SAN CARLOS,, CA, March 09, 2012 /24-7PressRelease/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in PK/PD and drug-disease modeling and simulation, today announced that results from its PK/PD collaboration with Pfizer will be presented as a poster at the 2012 American Society for Clinical Pharmacology and Therapeutics annual meeting in National Harbor, Maryland. The poster entitled "Role of Myostatin Pathway in Muscle Growth: Key Learnings from Retrospective Analysis of MYO-029 Preclinical and Clinical Data Thru PK/PD Modeling" will be presented March 17, 2012. The poster describes PK/PD and other analysis of ACE-031, an Fc fusion of ActRIIB decoy receptor of myostatin in animal species and humans, and describes the positive impact the analysis has had in guiding further development.

"We are pleased to have Pfizer present these results from our collaboration. This work clearly demonstrates the importance and impact of incorporating pharmacometrics and modeling into the drug development process," said Dr. Toufigh Gordi, President, PK/PD and Clinical Pharmacology Services.